Litcius/Paper detail

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion

Zenon Konteatis, Jeremy Travins, Stefan Größ, Katya Marjon, Amelia Barnett, Everton Mandley, Brandon Nicolay, Raj Nagaraja, Yue Chen, Yabo Sun, Zhixiao Liu, Jie Yu, Zhixiong Ye, Fan Jiang, Wentao Wei, Fang Cheng, Yi Gao, Peter Kalev, Marc L. Hyer, Byron DeLaBarre, Lei Jin, Anil K. Padyana, Lenny Dang, Joshua Murtie, Scott A. Biller, Zhihua Sui, Kevin M. Marks

2021Journal of Medicinal Chemistry97 citationsDOIOpen Access PDF

Abstract

into current clinical studies (ClinicalTrials.gov NCT03435250).

Topics & Concepts

Methionine AdenosyltransferaseChemistryCDKN2AAllosteric regulationEnzymeCancer researchPotencyMethionineSmall moleculeKinaseCancerBiochemistryIn vitroGeneBiologyGeneticsAmino acidCancer-related gene regulationEpigenetics and DNA MethylationRNA modifications and cancer
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion | Litcius